First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
48actual
Sites
2
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-11-23 | actual | When the study began enrolling |
| Primary completion | 2025-08-29 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-29 | actual | The whole study's end, after follow-up |
| First posted | 2022-10-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Volunteers
- Hepatic Steatosis
Interventions
- Drug: NNC0581-0001
- Drug: Placebo (NNC0581-0001)
Primary outcome
what the primary-completion date above is the date OFNumber of treatment emergent adverse events (TEAEs)
measured From dosing (Day 1) until completion of the End of Study Visit at week 52
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed